Sun Pharma Advanced Research Company Limited operates as a pharmaceutical research and drug discovery company in India. It develops SUN 1334H, which has completed phase II clinical studies, used in the treatment of allergic disorders, such as seasonal and perennial allergic rhinitis, urticaria, hay fever, conjunctivitis, and pruritis; and SUN-597, an anti-inflammatory glucocorticoid that has completed preclinical development and used for the treatment of allergic rhinitis and asthma, as well as for other applications. The company also develops SUN-44, a pro-drug of gabapentin, which is used for the treatment of neuropathy and seizures; SUN-09, a prodrug of baclofen that has completed phase I studies used as a skeletal muscle relaxant for the treatment of spasticity related to CNS disorders; and SUN K706, a novel tyrosine kinase inhibitor, which is in the stage of preclinical studies for the treatment of chronic myelogenous leukemia. Its drug delivery systems platform technologies that are under development include gastro retentive system, which allows longer retention in the stomach and enhances gastrointestinal absorption of drugs; wrap matrix system for controlled release of dosage; nanotechnology based delivery systems that enables selective delivery of cytotoxic drugs to cancerous tissues; biodegradable injections/ implants; swollen micelle microemulsion based latanoprost for the treatment of glaucoma; and dry powder inhalation device, which enables the dose administration of drugs for asthma and COPD. Sun Pharma Advanced Research Company Limited was incorporated in 2006 and is based in Vadodara, India.

Key Statistics